Age-related Macular Degeneration (AMD) Drugs Market Key Players Analysis- Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche AG (Switzerland), Novartis AG (Switzerland), Apellis Pharmaceuticals, Inc. (US).

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Age-related Macular Degeneration (AMD) Drugs Market Size, Share & Trends Analysis Report By Products (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre, Other Products), Molecules (Ranibizumab, Aflibercept, Faricimab, Pegcetoplan, Other Molecules), Type of AMD (Wet AMD, Dry AMD), Approval type (Biologic, Biosimilar) End User (Hospitals, Specialty Centers, Long-Term Care Facilities)- Market Outlook And Industry Analysis 2031"

The Global Age-related Macular Degeneration (AMD) Drugs Market is valued at US$ 9.58 Bn in 2023, and it is expected to reach US$ 19.77 Bn by 2031, with a CAGR of 9.7% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2854

Age-related Macular Degeneration is a gradually progressive eye disease that attacks mainly the older population causing some degeneration of the macula, which is the part of the retina used for sharp central vision. There are two types: dry AMD that appears to be the more common type characterized by slow gradual loss of vision and wet AMD, characterized by sudden vision changes due to the growth of the abnormal blood vessel underneath the retina. The AMD drugs market focuses mainly on anti-VEGF therapies, such as Eylea and Lucentis for wet AMD, whereas new advances such as Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) give new hope to patients suffering from dry AMD, previously treated underrepresented within the disease.

The significance of AMD drugs is that they delay disease progression. The anti-VEGF treatments with wet AMD work with the mechanism of inhibiting new abnormal blood vessels from growing; newer treatment options for dry AMD are focused on geographic atrophy and macular degeneration. Factors encouraging growth in the AMD drugs market include an aging population, lifestyle factors that contribute to increasing prevalence of AMD, and research discoveries that lead to novel therapies. Introducing new treatments, especially dry AMD, presents a better opportunity to advance outcomes for patients to be assured that there are great options available for preserving vision and improving quality of life for those affected.

List of Prominent Players in the Age-related Macular Degeneration (AMD) Drugs Market:
• Regeneron Pharmaceuticals Inc. (US)
• Bayer AG (Germany)
• F. Hoffmann-La Roche AG (Switzerland)
• Novartis AG (Switzerland)
• Apellis Pharmaceuticals, Inc. (US)
• Coherus BioSciences, Inc. (US)
• Astellas Pharma Inc. (Japan)
• Biogen (US)
• STADA Arzneimittel AG (Germany)
• Formycon AG (Germany)
• Biocon. (India)
• Outlook Therapeutics, Inc. (US)
• Intas Pharmaceuticals Ltd. (India)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Chengdu Kanghong Biotech Company (China)
• Sandoz Group AG (Switzerland)
• Stealth BioTherapeutics Inc. (US)
• Ocular Therapeutix, Inc. (US)
• Opthea Limited, Inc. (Australia)
• Kodiak Sciences Inc. (US)
• Innovent Biologics, Inc. (China)
• Bio-Thera Solution Inc. (China)
• Alvotech (Iceland)
• Alteogen Inc. (South Korea)
• Shanghai Henlius Biotech, Inc. (China)
• Amgen Inc. (US)
• Ocumension Therapeutics. (China)
• Adverum Biotechnologies, Inc. (US)

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics:
Drivers-
The Age-related Macular Degeneration (AMD) drugs market shows a strong growth rate, with various primary factors encouraging the same. There is a rising prevalence of AMD globally, especially among growing older populations, due to unhealthy lifestyle issues such as dietary lapses, smoking, and inactivity. Improvements in drug development-approvals of new innovative therapies such as Pegcetacoplan (Syfovre) and Avacincaptad Pegol (IZERVAY)-for dry AMD, along with long-acting anti-VEGF treatments for wet AMD, are increasing options and leading to a better effectiveness in treatment. More aggressive reimbursement policies have made treatments more accessible, which encourages patients to continue prescribed regimens. The market is bound to expand in new emerging regions of Asia Pacific and Latin America, and higher investment in R&D for novel therapies will open opportunities. Public-private partnerships are helping innovate, and the patient-centric shift would raise more demand for treatment plans tailored to the individual's needs. This, in turn, improves satisfaction and adherence levels, thus giving impetus to further growth in the market.

Challenges:
The treatments for Age-related Macular Degeneration (AMD) have challenges that may impede growth and limit access for patients. Exorbitant treatment costs, particularly in anti-VEGF therapies including Eylea and Vabysmo, curb access and promote nonadherence because it is cheaper for patients to use the off-label preparation of the drug, while dry AMD has been undertreated for quite some time, thus limiting the scope of the market.

Regional Trends:
North American leadership in Age-related Macular Degeneration (AMD) drugs is linked with strong pharmaceutical R&D, driven by large firms and research organizations that focus on novel therapies. The levels of research spending are also very high, hence such fast-paced drug development and approval, such as in the case of Enzeevu, which is a biosimilar for wet AMD. Advanced healthcare infrastructure, with dedicated facilities and tools for diagnosis, is another reason for such effective care and early intervention in the region. This positive regulatory environment, in large part driven by the FDA's increased aggressiveness in approving new therapies, further underlines market growth. Improvement in reimbursement policies and public-private partnerships for greater accessibility and affordability for the patient also significantly contribute to adherence, spreading innovation, and bettering the overall treatment paradigm.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2854

Recent Developments:
• In August 2023, Regeneron Pharmaceuticals announced that the U.S. FDA has approved EYLEA HD (aflibercept) 8 mg for treating wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR).
• In March 2022, Novartis announced that the European Commission (EC) has approved Beovu® (brolucizumab) 6 mg for treating visual impairment due to diabetic macular edema (DME), marking its second EC-approved indication following wet age-related macular degeneration in 2020.

Segmentation of Age-related Macular Degeneration (AMD) Drugs Market-
By Products:
• Lucentis
• Eylea & Eylea HD
• Vabysmo
• Syfovre
• Other Products
By Molecules:
• Ranibizumab
• Aflibercept
• Faricimab
• Pegcetoplan
• Other Molecules
By Type of AMD:
• Wet AMD
• Dry AMD
By Approval type:
• Biologic
• Biosimilar
By End User:
• Hospitals
• Specialty Centers
• Long-Term Care Facilities
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.